Assessing the risks and benefits of herbal medicine: An overview of scientific evidence

Alternative Therapies in Health and Medicine

Volumn 5, Issue 4, 1999, Pages 40-49

  Barrett, Bruce ^a   Kiefer, David ^b   Rabago, David ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Swedish Family Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT; VALERIAN;

ANGIOSPERM; GARLIC; GINKGO BILOBA; HUMAN; MEDICINAL PLANT; REVIEW; RISK ASSESSMENT;

GARLIC; GINKGO BILOBA; HUMANS; PLANT EXTRACTS; PLANTS, MEDICINAL; RISK ASSESSMENT; THEALES; VALERIAN; ZINGIBERALES;

EID: 0033158317     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Ernst E. Complementary Medicine: An Objective Appraisal. Oxford, England: Butterworth-Heinemann; 1996.
2. PDR for Herbal Medicines. Montvale. NJ: Medical Economics Company; 1998.
3. Levin JS, Glass TA, Kushi LK, Schuck JR, Steele LS, Jonas WB. Quantitative methods in research on complementary and alternative medicine: a methodological manifesto. Med Care. 1997;35:1079-1094.
4. Schulz V, Hänsel R, Tyler VE. Rational Phototherapy: A Physician's Guide to Herbal Medicine. Berlin, Germany: Springer-Verlag; 1998.
5. Spencer JW, Jacobs JJ. Complementary/Alternative Medicine: An Evidence-Based Approach. St Louis, Mo: Mosby, Inc; 1999.
6. Tyler VE. Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: Pharmaceutical Products Press/Haworth Press; 1994.
7. Blumenthal M, Goldberg A, Gruenwald J, et al, eds. German Commission E Monographs: Therapeutic Monographs on Medicinal Plants for Human Use. Austin, Tex: American Botanical Council; 1998.
8. Keller K. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany. J Ethnopharmacol. 1991;32:225-229.
9. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:1548-1553.
10. Brevoort P. The US botanical market: an overview. HerbalGram. 1996;36:49-57.
11. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
12. Eisenberg DM, Dans RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998;280:1569-1575.
13. Brevoort P. The booming US botanical market: a new overview. HerbalGram. 1998;44:33-46.
14. Johnston B. One-third of nation's adults use herbal remedies: market estimated at $3.24 billion. HerbalGram. 1997;40:52.
15. Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA. 1995;273:607-609.
16. De Smet PAGM, Brouwers JRBJ. Pharmacokinetic evaluation of herbal remedies. Clin Pharmacokinet. 1997;32:427-436.
17. De Smet PAGM, Keller K, Hansel R, Chandler RF. Adverse Effects of Herbal Drugs. Vol 3. Berlin, Germany: Springer-Verlag; 1997.
18. Brinker F. Herb Contraindications and Drug Interactions. Sandy, Ore: Eclectic Institute; 1997.
19. Akerele O. The WHO Traditional Medicine Programme: Policy and Implementation: International Traditional Health Newsletter. Geneva, Switzerland: World Health Organization; 1985;1:1.
20. Duke JA. Promising phytomedicinals. J Naturopathic Med. 1991;2:48-52.
21. Farnsworth NR. The role of ethnopharmacology in drug development. In: Chadwick D, Marsh J, eds. Bioactive Compounds From Plants (Ciba Symposium 154). New York, NY: Wiley; 1990.
22. Farnsworth N, Socjarto D. Global importance of medicinal plants. In: Akerele O, ed. Conservation of Medicinal Plants. Cambridge, England: Cambridge University Press; 1991.
23. Huxtable R. Plants, drugs and pioneers. HerbalGram. 1993;29:46-49.
24. Jones SFA. Herbs - useful plants: their role in history, Eur J Gastroenterol Hepatol. 1996;8:1227-1231.
25. Lewis WH, Elvin-Lewis MPF. Medical Botany: Plants Affecting Man's Health. New York, NY: John Wiley & Sons; 1977:515.
26. Schultes RE, von Reis S. Ethnobotany: Evolution of a Discipline. Portland, Ore: Dioscorides Press; 1995:414.
27. Solecki RS, Shanidar IV. A Neanderthal flower burial in northern Iraq. Science. 1975;190:880.
28. Unschuld PU. Medicine in China: A History of Ideas. Berkeley, Calif: University of California Press; 1985.
29. Ackerknecht EH. Therapeutics: From the Primitive to the Twentieth Century. New York, NY: Hafher Press; 1973.
30. Emboden WA. Art and artifact as ethnobotanical tools in the ancient Near East with emphasis on psychoactive plants. In: Schultes RE, von Reis S, eds. Ethnobotany: Evolution of a Discipline. Portland, Ore: Dioscorides Press; 1995.
31. Blumenthal M, King P. Ma huang, ancient herb, modern medicine, regulatory dilemma. HerbalGram. 1995;3432-27.
32. Chen KK, Schmidt CF. Epinephrine and related substances. Medicine. 1930;9:1-117.
33. Hien TT, White NJ. Qinghaosu. Lancet. 1993;341:603-608.
34. Qinghaosu antimalarial coordinating research group: antimalarial studies on qinghaosu. Chin Med J. 1979;92:811-816.
35. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med. 1996;335:76-83.
36. Luxemburger C, Nosten F, Rainmond SD, Chongsuphajaisiddhi T. White NJ. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. Am J Trop Med Hyg. 1995;53:522-525.
37. Nguyen DC, Dao BH, Nguyen PD, et al. Treatment of malaria in Vietnam with oral artemisinin. Am J Trop Med Hyg. 1993;48:398-402.
38. Van Hensbroek MB, Onyirah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med. 1996;335:69-75.
39. Foster S. Echinacea: Nature's Immune Enhancer. Rochester, Vt: Healing Arts Press; 1991:150.
40. Bauer R. Echinacea drogen - Wirkungen und wirksubstanzen [Echinacea drugs -effects and active ingredients]. Zeitschrift fur Arztliche Fortbildung. 1996;90:111-115.
41. Elsasser-Beile U, Willenbacher W, Bartsch HH, Gallati H, Schulte Monting J, Vo S. Cytokine production in leukocyte cultures during therapy with echinacea extract. J Clin Lab Anal. 1996;10:441-445.
42. Luettig B, Steinmuller C, Gifford GE, Wagner H, Lohman-Matthes ML. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst. 1989;81:669-675.
43. Melchart D, Linde K, Worku F, et al. Results of five randomized studies on the immunomodulatory activity of preparations of echinacea. J Altern Complement Med. 1995;1:145-160.
44. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or AIDS patients. Immunopharmacology. 1997;35:229-235.
45. Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. In: Wagner H, Farnsworth NR, eds. Economic and Medicinal Plant Research. New York, NY: Academic Press Limited; 1991.
46. Bauer R. Echinacea: biological effects and active principles. In: Lawson LD, Bauer R. eds. Phytomedicines of Europe: Chemistry and Biological Activity. Washington, DC: American Chemical Society; 1998:140-157.
47. Melchart D, Linde K, Worku F, Bauer R, Wagner H. Immunomodulation with echinacea: a systematic review of controlled trials. Phytomedicine. 1994;1:245-254.
48. Melchart D, Walther E, Linde K, Brandmaier R. Lersch C. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med. 1998;7:541-545.
49. Bräunig B, Dorn M, Limburg E, Knick E, Bausendorf. Echinaceae purpureae radix: zur Stärkung der körpereigenen Abwehr bei grippalen Infekten. Z Phytother. 1992;13:7-13.
50. Bräunig B, Knick E. Therapeutische Erfahrungen mit Echinaceae pallidae bei grippalen Infekten. Naturheilpraxis. 1993;1:72-75.
51. Dorn M. Milerung grippaler Effeckte durch ein pflanzliches Immunstimulans. Nuturund Ganzheitsmedizin. 1989;2:314-319.
52. Hoheisel O, Sandberg M, Bertram S, Bulitta M, Schäfer M. Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial. Eur J Clin Res. 1997;9:261-268.
53. Reitz HD. Immunmodulatoren mit pflanzlichen Wirkstoffen: eine wissenschaftliche Studie am Beispiel Esberitox N. Notabene Medici. 1990;20:362-366.
54. Vorberg G. Bei Erkältung unspezifische Immunabwehr stimulieran: doppelblindstudie zeigt: das bewährte phytotherapeutikum esberitox verkürzt die symptommatik. Arztl Praxis. 1984;36:97-98.
55. Vorberg G, Schneider B. Pflanzliches Immunstimulans verkürzt grippalen Infeckt. Doppelblindstudie belegt die Steigerung der unspezifischen Infektabwehr. Arztl Forsch. 1989:36:3-8.
56. Mengs U, Clare CB, Poiley JA. Toxicity of Echinacea purpurea. Arzneim-Forsch/Drug Res. 1991;41(10):1076-1081.
57. Parnham MJ. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long-term oral immunostimulation. Phytomedicine. 1996;3:95-102.
58. Koch HP. In: Lawson LD, ed. Garlic: The Science and Therapeutic Application of Allium Sativum L and Related Species. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996.
59. Agarwal KC. Therapeutic actions of garlic constituents. Med Res Rev. 1996;16:111-124.
60. Gebhardt R. Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatoqtes. Lipids. 1993;28:613-619.
61. Auer W. Hypertension and hyperlipidemia: garlic helps in mild cases. Br J Clin Pract. 1990;44:3-6.
62. Silagy C, Neil A. Garlic as a lipid lowering agent: a meta-analysis. J R Coll Physicians Land. 1994;28:39-45.
63. Warshafsky S, Kramer RS, Sivak SL. Effect of garlic on total serum cholesterol: a meta-analysis. Ann Intern Med. 1993;119:599-605.
64. Neil H A, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipemia: a controlled trial and meta-analysis. J R Coll Physicians Lond. 1996;30:329-334.
65. Berthold HK, Sudhop T, von Bergmann K. Effects of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA. 1998;279:1900-1902.
66. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, controlled trial. Arch Intern Med. 1998;158:1189-1194.
67. Simons LA, Balasbramaniam S, von Konigsmark M, Paerfitt A, Peters J. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolemia. Atherosclerosis. 1995;113:219-225.
68. Silagy CA, Neil HAW. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463-468.
69. Steiner M, Kahn AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr. 1996;64(6):866-870.
70. Corrigan D. Zingiber officinale. In: De Smet PAGM, Keller K, Hansel R, Chandler RF, eds. Adverse Effects of Herbal Drugs. Berlin, Germany: Springer-Verlag; 1997.
71. Mowrey DB, Clayson DE. Motion sickness, ginger, and psychophysics. Lancet. 1982;1:655-657.
72. Wood CD, Manno JE, Wood MJ, Manno BR, Mims ME. Comparison of efficacy of ginger with various antimotion sickness drugs. Clin Res Prac Drug Reg Aff. 1988;6:129-136.
73. Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology. 1991;42:111-120.
74. Stott JRR, Hubble MP, Spense MB. A double-blind comparative trial of powdered ginger root, hyoscine hydrobromide and cinnarizine in the prophylaxis of motion sickness induced by cross coupled stimulation. Proc Advisory Group Aerosp Res Dev. 1985;372(39):1-6.
75. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness: a controlled trial on the open sea. Acta Otolaryngol. 1988;105:45-49.
76. Bone ME, Wilkinson DJ, Young JR, McNeil J, Charlton S. The effect of ginger root on post-operative nausea and vomiting after major gynaecological surgery. Anaesthesia. 1990;45:669-671.
77. Phillips S, Ruggier R, Hutchinson SE. Zingiber officinale (ginger) - an antiemetic for day case surgery. Anaesthesia. 1993;48(8);715-717.
78. Arfeen Z, Owen H, Plummer JL, Ilsley AH, Sorby-Adams RA, Doecke CJ. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intensive Care. 1995;23:449-452.
79. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1990;38:19-24.
80. Fulder S, Tenne M. Ginger as an anti-nausea remedy in pregnancy: the issue of safety. Hertal Gram. 1997;38:47-50.
81. Huxtable R. The pharmacology of extinction. J Ethnopharmacol. 1992;37:1-11.
82. Woerdenbag HJ, Van Beck TA. Gingko biloba. In: De Smet PAGM, Keller K, Hansel R, Chandler RF, eds. Adverse Effects of Herbal Drugs. Berlin, Germany: Springer-Verlag; 1997.
83. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34:352-358.
84. Rai GS, Shovelin C, Wesnes KA. A double blind, placebo-controlled study of ginkgo biloba extract in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin. 1992;12:350-355.
85. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type: a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol. 1994;9:215-222.
86. Kanowski S, Hermann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the Gingko biloba special extract EGb 761 in outpatients suffering from mild to moderate primary dementia of the Alzheimer type or multi-infarct dementia. Phytomedicine. 1997;4:3-13.
87. Maurer K, Ihl R, Dierks T, Frölich L Clinical efficacy of ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res. 1997;31:645-655.
88. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind randomized trial of an extract of ginkgo biloba for dementia. JAMA. 1997;278:1327-1332.
89. Ginkgo biloba for dementia. Med Lett Drugs Ther. 1998;40(1029):63-65.
90. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St Johns wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ. 1996;313:253-258.
91. Wheatley D. LI 160, an extract of St John's wort, versus amitriptyline in mildly to moderately depressed outpatients: a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30(suppl2):77-80.
92. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30(suppl 2):81-85.
93. De Smet PAGM, Nolen WA. St John's wort as an antidepressant. BMJ. 1996;313:241-242.
94. St John's wort. Med Lett Drugs Ther. 1997;39:107-108.
95. Houghton P. The biological activity of valerian and related plants. J Pharmacol. 1988;22:121-142.
96. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17:65-71.
97. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Medica. 1985;50:144-147.
98. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav. 1989;32:1065-1066.
99. Panijel M. Randomisierte doppleblindstudie zum klinischen wirksamkeitvergleich eines phytotherapeutikums mit diazepam. Therapicwoche. 1985;35:4659-1669.
100. Schulz H, Stolz C, Miller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. 1994;27:147-151.
101. Bos R, Woerdenbag HJ, De Smet PAGM, Scheffer JJC. Valeriana species. In: De Smet PAGM, Keller K, Hansel R, Chandler RF, eds. Adverse Effects of Herbal Drugs. Berlin, Germany: Springer-Verlag; 1997.
102. Reichert RG. Valerian clinical monograph. Q Rev Nat Med. Fall 1998:207-215.
103. Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies [editorial]. N Engl J Med. 1998;339:839-841.
104. Bone K. Adverse reaction reports. Mod Phytotherapist. 1997;4:34-36.
105. D'Epiro NW. Herbal medicine: what works, what's safe. Patient Care. October 15, 1997:49-68.
106. Farnsworth NR. Relative safety of herbal medicines. HerbalGram. 1993;29(suppl):36A-36H.
107. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274:29-34.
108. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324:370-376.
109. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:307-311.
110. Ernst E. Harmless herbs? A renew of the recent literature. Am J Med. 1998;104:170-178.
111. Litovitz T, Manoguerra A. Comparison of pediatric poisoning hazards: an analysis of 3.8 million exposure incidents. Pediatrics. 1992;89:999-1006.
112. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet. 1998;351:643.
113. Tyler VE. What pharmacists should know about herbal remedies. J Am Pharm Assoc. 1996;NS36:29-37.
114. Jonas WB. Alternative medicine: learning from the past, examining the present, advancing to the future. JAMA. 1998;280:1616-1617.
115. Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med. 1997;127:61-69.
116. McNaughton C, Eidsness LM. Ethics of alternative therapies. S D J Med. 1995;48:209-211.
117. Starr P. The Social Transformation of American Medicine. New York, NT: Basic Books; 1982.
118. Wolinsky H, Brune T. The Serpent and the Staff: The Unhealthy Politics of the American Medical Association. New York, NY: GP Putnam & Sons; 1994.